best glp-1 agonist companies Receptor Market Size & Analysis, 2026-2033 Top 12 Pharma: Pfizer Tops

It will be interesting to see where healthcare organizations land on some of these questions, since many are in the unique position of both sponsoring health coverage and providing actual care to their employees

The reduction of cardiovascular events is not only related to anti-diabetic properties, but also to pleotropic effects leading to the reduction of the residual cardiovascular risk, that has been defined as the risk of progression of CV events (MACE or HF) that remains after the optimal glycaemic control in T2DM patients, and it seems to be related to meta-inflammation, defined as a low-grade chronic and sterile inflammatory status

J Clin Endocrinol Metab 2025

The starting dose is 0.25 milligrams for 4 weeks before increasing the dosage to 0.5 milligrams

Epub 2024 Jan 5

NINA MOINI: Why might older adults in particular benefit from greater access to these GLP-1s